近日,液体活检知名企业Guardant Health公布了其ECLIPSE研究的关键性数据,此项前瞻性注册研究入组量达2万人,通过血液检查的方式筛查结直肠癌,以验证产品性能。 ECLIPSE研究数据表明,Guardant Health的结直肠癌筛查产品ShieldTM在一般人群中筛查结直肠癌的检测灵敏...
A More Pleasant Way to Screen for Colon Cancer You can now screen at any healthcare visit with Shield, the first FDA-approved blood test for colon cancer covered by Medicare. Request Shield Conquering Cancer With Data Through the power of blood tests, we can uncover clues that allow doctors...
Our Approach to ESG Our mission — to conquer cancer with data — is at the heart of our ESG commitment and is fully integrated into our business strategy. Our passion to improve human health is foundational to our approach to ESG. We have laid out the following initiatives as part of our...
Guardant Health, Inc. and its affiliated entities (“Guardant Health”, “Guardant”, “we”, “us”, or “our”) respects the privacy of those who use our Services. This Privacy Policy (“Policy”) informs you of our policies regarding the collection, use, and disclosure of Personal Data...
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
Guardant Health is a leading precision medicine company focused on transforming patient care and conquering cancer with data.
/PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced that it has launched its blood-based colorectal cancer...